Finding new ways to treat advanced prostate cancer
Testing ATAD2 as a new therapeutic target for advanced prostate cancer
This research looks for new treatments for advanced prostate cancer, especially forms that no longer respond to standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11127423 on NIH RePORTER |
What this research studies
Prostate cancer is a serious health concern for men, and advanced forms of the disease, particularly those resistant to hormone therapy, are very difficult to treat. This often leads to a more aggressive type called neuroendocrine prostate cancer (NEPC), which currently has no cure. Our team has found a protein called ATAD2 that is more active in these aggressive cancers. We are exploring if blocking ATAD2 with new medicines can stop cancer growth and offer a new path for patients.
Who could benefit from this research
Good fit: This research is focused on understanding and treating advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC).
Not a fit: Patients with early-stage prostate cancer that is responsive to standard hormone therapies may not directly benefit from this specific research at its current stage.
Why it matters
Potential benefit: If successful, this work could lead to new medications for advanced prostate cancer, especially for patients whose cancer has become resistant to current treatments.
How similar studies have performed: Preliminary studies have shown that ATAD2 inhibitors can dramatically suppress the growth of neuroendocrine prostate cancer cells and tumors in laboratory settings.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.